ArticleNIHR open research2022

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial.

Paul Gravestock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.